2. Cell Cycle/DNA Damage Apoptosis Autophagy Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. PERK Apoptosis Autophagy Reactive Oxygen Species (ROS) Caspase Bcl-2 Family
  4. Anticancer agent 296

Anticancer agent 296 is a potent anticancer agent that activates the PERK-eIF2α-CHOP signaling pathway to induce endoplasmic reticulum stress, thereby regulating caspase and Bcl-2 family proteins, ultimately leading to apoptosis. Anticancer agent 296 increases intracellular levels of reactive oxygen species (ROS), reduces mitochondrial membrane potential, and promotes Ca2+ release. Anticancer agent 296 suppresses cell colony formation and S-phase cell proliferation, and induces autophagy. Anticancer agent 296 is applicable for research on non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

Anticancer agent 296

Anticancer agent 296 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 296 Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 296 is a potent anticancer agent that activates the PERK-eIF2α-CHOP signaling pathway to induce endoplasmic reticulum stress, thereby regulating caspase and Bcl-2 family proteins, ultimately leading to apoptosis. Anticancer agent 296 increases intracellular levels of reactive oxygen species (ROS), reduces mitochondrial membrane potential, and promotes Ca2+ release. Anticancer agent 296 suppresses cell colony formation and S-phase cell proliferation, and induces autophagy. Anticancer agent 296 is applicable for research on non-small cell lung cancer (NSCLC)[1].

In Vitro

Anticancer agent 296 (Compound 5b) (1.25-10 μM; 48 h) potently inhibits proliferation of A549 and HeLa cancer cells with IC50 values of 3.88 μM and 3.89 μM, respectively, and has a favorable safety margin against normal cells[1].
Anticancer agent 296 (1.94-3.88 μM; 48 h; 24 h with Mitomycin C (HY-13316) pre-treatment) effectively inhibits migration of A549 cells in a concentration-dependent manner, with 3.88 μM reducing wound healing to 8.19%[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) downregulates FAK protein expression in A549 cells, contributing to inhibited migration, and also activates the PERK-eIF2α-CHOP ER stress pathway and the endogenous apoptotic pathway in A549 cells by regulating key proteins[1].
Anticancer agent 296 (1.94-7.76 μM; 7 days) effectively inhibits colony formation of A549 cells at concentrations ≥3.88 μM[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) activates autophagy in A549 cells by upregulating Beclin-1 and promoting LC3 I/II conversion[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) induces S phase arrest in A549 cells in a dose-dependent manner, with 7.76 μM increasing S phase to 31.33% by downregulating cell cycle-related proteins[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) decreases mitochondrial membrane potential in A549 cells in a concentration-dependent manner[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) increases ROS levels in A549 cells[1].
Anticancer agent 296 (3.88-7.76 μM; 24 h) induces oxidative stress in A549 cells by reducing GSH and increasing MDA levels[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) increases intracellular calcium concentration in A549 cells, with 7.76 μM inducing a 1.68-fold increase[1].
Anticancer agent 296 (3.88 μM; 24 h) induces endoplasmic reticulum stress in A549 cells via the PERK pathway, as evidenced by ER vacuolization[1].
Anticancer agent 296 (1.94-7.76 μM; 24 h) induces early apoptosis in A549 cells, with 7.76 μM increasing early apoptosis to 11.14%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 296 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: A549 (human lung adenocarcinoma), HeLa (human cervical cancer), NIH-3T3 (mouse embryonic fibroblast), THLE-2 (human immortalised liver)
Concentration: 1.25 μM, 2.5 μM, 5 μM and 10 μM
Incubation Time: 48 h
Result: Potently inhibited proliferation of A549 and HeLa cells with IC50 values of 3.88 μM and 3.89 μM, respectively.
Exhibited lower cytotoxicity against normal cells with IC50 values of 26.48 μM (NIH-3T3) and 12.08 μM (THLE-2).

Cell Migration Assay[1]

Cell Line: A549 cells
Concentration: 1.94 μM (0.5×IC₅₀), 3.88 μM (IC₅₀)
Incubation Time: 48 h; 24 h (with mitomycin c pre-treatment)
Result: Reduced scratch healing percentage from 29.31% (control) to 18.16% (1.94 μM) and 8.19% (3.88 μM) after 48 h. Inhibited migration even in the presence of Mitomycin c.

Western Blot Analysis[1]

Cell Line: A549 cells
Concentration: 1.94 μM (0.5×IC₅₀), 3.88 μM (IC₅₀), 7.76 μM (2×IC₅₀)
Incubation Time: 24 h
Result: Downregulated FAK protein expression compared to the control group.\nUpregulated p53, Bax, cleaved PARP, caspase-3, PERK, GRP78, p-eIF2α, CHOP, STIM1, and ORAI1; downregulated Bcl-2.

Cell Autophagy Assay[1]

Cell Line: A549 cells
Concentration: 1.94 μM (0.5×IC₅₀), 3.88 μM (IC₅₀), 7.76 μM (2×IC₅₀)
Incubation Time: 24 h
Result: Increased MDC fluorescence intensity (indicating enhanced autophagy) and upregulated Beclin-1 expression, while p62 decreased and LC3 I/II conversion was observed.

Cell Cycle Analysis[1]

Cell Line: A549 cells
Concentration: 1.94 μM (0.5×IC₅₀), 3.88 μM (IC₅₀), 7.76 μM (2×IC₅₀)
Incubation Time: 24 h
Result: Increased S phase percentage from 18.95% (control) to 24.72% (1.94 μM), 27.38% (3.88 μM), and 31.33% (7.76 μM). Reduced expression of Cyclin A2, Cyclin B1, and CDK2.

Apoptosis Analysis[1]

Cell Line: A549 cells
Concentration: 1.94 μM (0.5×IC₅₀), 3.88 μM (IC₅₀), 7.76 μM (2×IC₅₀)
Incubation Time: 24 h
Result: Increased early apoptosis rate from 2.48% (control) to 4.47% (1.94 μM), 9.34% (3.88 μM), and 11.14% (7.76 μM).
In Vivo

Anticancer agent 296 (Compound 5b) (10-20 mg/kg; i.p.; daily; 12 consecutive days) exhibits dose-dependent antitumor efficacy in A549 xenograft mice, with 20 mg/kg achieving an 80.32% tumor inhibition rate[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nu mice injected with A549 cells[1]
Dosage: 10 mg/kg; 20 mg/kg
Administration: i.p.; daily; 12 consecutive days
Result: Achieved tumor inhibition rates of 62.92% (10 mg/kg) and 80.32% (20 mg/kg). Induced DNA damage in tumor cells with γH2AX positive rates of 60.2% (10 mg/kg) and 69.3% (20 mg/kg). Inhibited tumor proliferation with Ki67 positive rates of 36.5% (10 mg/kg) and 24.4% (20 mg/kg). Observed no significant body weight changes or chronic organ damage.
Molecular Weight

519.43

Formula

C24H22BrF3N2OSi
SMILES

COC1=CC=CC2=C1C(C(C3=CNC4=CC=C(C=C43)Br)(C(F)(F)F)C#C[Si](C)(C)C)=CN2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 296 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 296Anticancer agent296Anticancer agent-296PERKApoptosisAutophagyReactive Oxygen Species (ROS)CaspaseBcl-2 FamilyProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseHeLaPERK-eIF2α-CHOP signaling pathwayapoptosisA549non-small cell lung cancerlung adenocarcinomareactive oxygen speciesmitochondrial membrane potentialendoplasmic reticulum stressInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 296
Cat. No.:
HY-181087
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.